Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Teva “Cautiously Optimistic” On Copaxone Despite Generic

This article was originally published in The Pink Sheet Daily

Executive Summary

The U.S. market share for Sandoz/Momenta’s generic version of Copaxone is under 5% of the total glatiramer market, Teva said during its second quarter sales and earnings call.

Advertisement

Related Content

Allergan Moves Into Busy CGRP Class By Buying Merck’s Oral Drugs

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register